Brand: MILBEWORM ®
CHEMICAL CLASS of the active ingredient(s):
INDICATIONS: DOGS and CATS
PARASITES CONTROLLED* (spectrum of activity):
- In dogs: Heartworm prevention (Dirofilaria spp), roundworms (Toxocara canis, Toxascaris leonina, Crenosoma vulpis, Angiostrongylus vasorum), hookworms (Ancylostoma caninum, Uncinaria stenocephala), whipworms (Trichuris vulpis), tapeworms (Dipylidium caninum, Taenia spp, Echinococcus multilocularis, Mesocestoides spp).
- In cats: Heartworm prevention (Dirofilaria spp), control of roundworms (Toxocara cati), hookworms (Ancylostoma tubaeformae) and tapeworms (Dipylidium caninum, Taenia spp, Echinococcus multilocularis, Mesocestoides spp).
- For treatment of Angiostrongylus vasorum infections, milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with the product and continue with the monovalent product containing milbemycin oxime alone, for the remaining three weekly treatments.
- For the treatment of Thelazia callipaeda, milbemycin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against cestodes is indicated, the product can replace the monovalent product containing milbemycin oxime alone.
* Can be slightly different in some countries: read the product label!
UK and other countries:
Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg given once orally.
- Dogs 0.5 to 1 kg bw: ½ tablet with 2.5 mg milbemycin oxime and 25 mg praziquantel (equivalent to 2.5 - 1.3 mg/kg milbemycin oxime and 25.0 - 13.0 mg/kg praziquantel)
- Dogs >1 to 5 kg bw: 1 tablet with 2.5 mg milbemycin oxime and 25 mg praziquantel (equivalent to 2.5 - 0.5 mg/kg milbemycin oxime and 25.0 - 5.0 mg/kg praziquantel)
- Dogs 5 to 10 kg bw: 2 tablet with 2.5 mg milbemycin oxime and 25 mg praziquantel (equivalent to 1.0 - 0.5 mg/kg milbemycin oxime and 10.0 - 5.0 mg/kg praziquantel)
- Dogs >5 to 25 kg bw: 1 tablet with 12.5 mg milbemycin oxime and 125 mg praziquantel (equivalent to 2.5 - 0.5 mg/kg milbemycin oxime and 25.0 - 5.0 mg/kg praziquantel)
- Dogs >25 to 50 kg bw: 2 tablets, each with 12.5 mg milbemycin oxime and 125 mg praziquantel (equivalent to 1.0 - 0.5 mg/kg milbemycin oxime and 10.0 - 5.0 mg/kg praziquantel)
- Dogs >50 to 75 kg bw: 3 tablets, each with 12.5 mg milbemycin oxime and 125 mg praziquantel (equivalent to 0.75 - 0.5 mg/kg milbemycin oxime and 7.5 - 5.0 mg/kg praziquantel)
- Cats 0.5 to 1 kg bw: ½ tablet with 4 mg milbemycin oxime and 10 mg praziquantel (equivalent to 4.0 - 2.0 mg/kg milbemycin oxime and 10.0 - 5.0 mg/kg praziquantel)
- Cats >1 to 2 kg bw: 1 tablet with 4 mg milbemycin oxime and 10 mg praziquantel (equivalent to 4.0 - 2.0 mg/kg milbemycin oxime and 10.0 - 5.0 mg/kg praziquantel)
- Cats 2 to 4 kg bw: ½ tablet with 16 mg milbemycin oxime and 40 mg praziquantel (equivalent to 4.0 - 2.0 mg/kg milbemycin oxime and 10.0 - 5.0 mg/kg praziquantel)
- Cats >4 to 8 kg bw: 1 tablet with 16 mg milbemycin oxime and 40 mg praziquantel (equivalent to 4.0 - 2.0 mg/kg milbemycin oxime and 10.0 - 5.0 mg/kg praziquantel)
- Cats >8 - 12 kg bw: 1½ tablets with 16 mg milbemycin oxime and 40 mg praziquantel (equivalent to 3.0 - 2.0 mg/kg milbemycin oxime and 7.0 - 5.0 mg/kg praziquantel)
* Can be slightly different in some countries: read the product label!
- LD50 (acute oral) in rats: n.a. for the tablets.
- Estimated Hazard Class according to the WHO: not applicable for veterinary medicines
Never use in cats tablets approved only for use in dogs, and vice-versa. Never use in cats or small dogs tablets approved for large animals. Learn more about tablets and their safety.
WARNING 1! All heartworm preventatives contain macrocyclic lactones, (e.g. ivermectin, milbemycin oxime, moxidectin, selamectin) which must be handled very carefully on dogs. The reason is that dogs of some breeds do not tolerate macrocyclic lactones or other medicines (e.g. emodepside) that can cross the blood-brain barrier. They can suffer more or less serious adverse effects if treated at dose rates slightly higher than the recommended ones. Consequently dosing must be as accurate as possible. This is the case for Collies and related breeds, which have a mutation in the MDR-1 gene that affects the blood-brain barrier and makes it more permeable to such compounds than in dogs without this mutation. Besides Collies, other dog breeds have shown similar problems, although the MDR-1 mutation has not been confirmed in all of them. The breeds more affected by this mutation are (% frequency): Collie (70%), Long-haired Whippet (65%), Australian Shepherd (50%, also mini), McNab (30%), Silken Windhound (30%), English Shepherd (15%), Shetland Sheepdog (15%), English Shepherd (15%), German Shepherd (10%), Herding Breed Cross (10%). Other less affected breeds are: Old English Sheepdog, Border Collie, Berger Blanc Suisse, Bobtail, Wäller. The only way to be sure that a dog breed is affected by this mutation or not, is to test for it. As more dogs are tested it is likely that the mutation is discovered in other breeds, or that the frequencies change.
WARNING 2! Heartworm preventatives stop development of microfilariae to adult worms but do not cure infections with adult worms. These preventative medicines are different from those curative anthelmintics that kill the adult worms. But preventatives may kill a few adult worms. If this happens, such dead worms may block lung vessels, which can be seriously harmful, even fatal for the pet. Consequently, heartworm preventatives are usually not administered to pets that are already infected with adult worms (hence the need for periodic diagnostic tests), because the risk of serious complications is real. The infection has first to be treated with adequate curative anthelmintics before preventative products are administered. This is however not trivial, and also risky for the same reason.
For these reasons, heartworm prevention should always be done under the supervision of a veterinary doctor.
Click here to learn more on heartworms.
You may be interested in the following articles in this site dealing with the general safety of veterinary products:
- Safety for humans
- Safety for domestic animals
- Safety for the environment
- Hazard classifications of pesticides
Risk of resistance development? YES
There are reports of resistance or tolerance of heartworm microfilariae (Dirofilaria spp) to ivermectin and other macrocyclic lactones such as milbemycin oxime in the USA (mainly in the South). This has happened after about 20 years of very intensive use of such compounds there. This may happen elsewhere as well. Currently there are no other once-a-month treatments for heartworm prevention other than those containing macrocyclic lactones.
Are the active ingredients of this product ORIGINAL* or GENERICS**?
- Milbemycin oxime: GENERIC (introduced in the 1980s)
- Praziquantel: GENERIC (introduced in the 1970s)
*Meaning that they are still patent protected and generics are not yet available
**Meaning that they have lost patent protection and may be acquired from manufacturers of generic active ingredients other than the holder of the original patent.
COUNTRIES where this product is marketed: UK and other EU other countries.
GENERIC BRANDS available? YES. MILBWORM itself is a generic version of MILBEMAX (introduced by NOVARTIS in the 1990s).
Click here to learn more about GENERIC vs. ORIGINAL drugs.
MILBEWORM from MIPET is a broad-spectrum wormer for dogs and cats including once-a-month heartworm prevention, a generic version of ELANCO's MILBEMAX.
Milbemycin oxime is a macrocyclic lactone effective against roundworms and some external parasites that was introduced in the late 1980s (by CIBA-GEIGY → NOVARTIS → ELANCO). It is exclusively used in pets, not in livestock or agriculture. As a general rule, due to a different pharmacokinetic behavior the anthelmintic effect is longer for milbemycin oxime than for ivermectin, although this strongly depends on the delivery form and the administered dose. A monthly treatment ensures adequate control of the roundworm species mentioned and prevents development of heartworm microfilariae.
Immature heartworms are transmitted to pets by mosquitoes that inject microfilariae (i.e. immature heartworms) during their blood meal. These microfilariae then migrate through the pet's tissues towards the blood vessels. At the recommended dose milbemycin oxime kills the migrating microfilariae in the tissues of the pets, but normally not the adult heartworms in the blood vessels. In contrast with ivermectin, at the therapeutic dose for heartworm prevention milbemycin oxime also controls several important parasitic roundworms (Toxocara canis, Toxascaris leonina), hookworms (Ancylostoma caninum) and whipworms (Trichuris vulpis) in dogs, as well as roundworms (Toxocara cati) and hookworms (Ancylostoma tubaeformae) in cats.
Praziquantel is a veteran isoquinoline anthelmintic introduced in the 1970s (by BAYER). Praziquantel adds efficacy against tapeworms (e.g. Dipylidium caninum, Taenia pisiformis, Echinococcus spp) but has no efficacy whatsoever against roundworms, hookworms or whipworms. It is the anthelmintic most vastly used against tapeworms in pets. There are hundreds of antiparasitic brands for pets containing praziquantel.
For an overview and a list of the most popular pet wormers click here.
This article IS NOT A PRODUCT LABEL. It offers complementary information that may be useful to veterinary professionals and users that are not familiar with veterinary antiparasitics.
Information offered in this article has been extracted from publications issued by manufacturers, government agencies (e.g. EMEA, FDA, USDA, etc.) or in the scientific literature. No guarantee is given on its accuracy, integrity, sufficiency, actuality and opportunity, and any liability is denied. Read the site's DISCLAIMER.
In case of doubt contact the manufacturer or a veterinary professional.